Skip to content

Clinical efficacy evaluation of Qingda Granule in the treatment of hypertension (grade 1, low to medium-risk) patients: a multicenter, randomized, double-blind, double-simulated, parallel-controlled, non-inferiority clinical study

Clinical efficacy evaluation of Qingda Granule in the treatment of hypertension (grade 1, low to medium-risk) patients: a multicenter, randomized, double-blind, double-simulated, parallel-controlled, non-inferiority clinical study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033890
Enrollment
Unknown
Registered
2020-06-15
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Sponsors

Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for essential hypertension measured in the same clinic, the hypertension is graded as grade 1, and the risk stratification is low to medium risk (refer to the 2018 Revision of Chinese Guidelines for The Prevention and Treatment of Hypertension); 2. Did not take or did not take blood pressure medicine regularly within one month; 3. Between 20 and 75 years old (including boundary value); 4. Agree to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with obvious liver and kidney diseases or with ALT and AST 1.5 times higher than ULN, Cr and BUN higher than ULN; 2. Patients with serious mental illness, hematopoietic disease, malignant tumor and other major diseases; 3. Women who are pregnant or preparing for pregnancy, and women who are breastfeeding; 4. Have participated in or are participating in other clinical researchers in the past three months; 5. Suspected or definite allergy to the study drug.

Design outcomes

Primary

MeasureTime frame
Systolic blood pressure decreased over 4 weeks after treatment;

Secondary

MeasureTime frame
Diastolic blood pressure drops over 4 weeks of treatment;Treatment 8 weekend systolic and diastolic blood pressure drop values;The blood pressure reached the target rate at the end of 4 and 8 weeks after treatment;Blood pressure control at 4 weeks and 8 weeks after treatment (24-hour ambulate blood pressure monitoring);The change of the total score of TCM syndrome score compared with that before medication (day 0);The change of Hamilton anxiety self-rated total score compared with that before medication (day 0);The changes of four hypertension hormones compared with those before medication (day 0);

Countries

China

Contacts

Public ContactChanggeng Fu

Xiyuan Hospital, China Academy of Chinese Medical Sciences

fucgbs@163.com+86 15101038490

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026